ImmunoGen Statistics
Share Statistics
ImmunoGen has 279.35M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 279.35M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 132 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 20.61M, so 7.38% of the outstanding
shares have been sold short.
| Short Interest | 20.61M |
| Short % of Shares Out | 7.38% |
| Short % of Float | 7.4% |
| Short Ratio (days to cover) | 5 |
Valuation Ratios
The PE ratio is -5.64 and the forward
PE ratio is null.
ImmunoGen's PEG ratio is
0.
| PE Ratio | -5.64 |
| Forward PE | n/a |
| PS Ratio | 11.55 |
| Forward PS | n/a |
| PB Ratio | 8.06 |
| P/FCF Ratio | -5.44 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
ImmunoGen has an Enterprise Value (EV) of 996.61M.
| EV / Sales | 9.16 |
| EV / EBITDA | -4.58 |
| EV / EBIT | -4.34 |
| EV / FCF | -4.31 |
Financial Position
The company has a current ratio of 2.26,
with a Debt / Equity ratio of 0.1.
| Current Ratio | 2.26 |
| Quick Ratio | 2.5 |
| Debt / Equity | 0.1 |
| Debt / EBITDA | -0.07 |
| Debt / FCF | -0.07 |
| Interest Coverage | -53.04 |
Financial Efficiency
Return on Equity is -143.06% and Return on Invested Capital is -129.83%.
| Return on Equity | -143.06% |
| Return on Assets | -63.89% |
| Return on Invested Capital | -129.83% |
| Revenue Per Employee | $392,714.8 |
| Profits Per Employee | $-804,797.83 |
| Employee Count | 277 |
| Asset Turnover | 0.31 |
| Inventory Turnover | -0.01 |
Taxes
| Income Tax | 1.22M |
| Effective Tax Rate | -0.55% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is 1.17, so ImmunoGen's
price volatility has been higher than the market average.
| Beta | 1.17 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 29.69 |
| 200-Day Moving Average | 19.27 |
| Relative Strength Index (RSI) | 82.52 |
| Average Volume (20 Days) | 8,287,745 |
Income Statement
In the last 12 months, ImmunoGen had revenue of 108.78M
and earned -222.93M
in profits. Earnings per share was -0.88.
| Revenue | 108.78M |
| Gross Profit | 108.61M |
| Operating Income | -220.89M |
| Net Income | -222.93M |
| EBITDA | -217.55M |
| EBIT | -217.55M |
| Earnings Per Share (EPS) | -0.88 |
Full Income StatementBalance Sheet
The company has 275.14M in cash and 15.24M in
debt, giving a net cash position of 259.89M.
| Cash & Cash Equivalents | 275.14M |
| Total Debt | 15.24M |
| Net Cash | 259.89M |
| Retained Earnings | -1.69B |
| Total Assets | 822.1M |
| Working Capital | 601.57M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -229.8M
and capital expenditures -1.36M, giving a free cash flow of -231.17M.
| Operating Cash Flow | -229.8M |
| Capital Expenditures | -1.36M |
| Free Cash Flow | -231.17M |
| FCF Per Share | -0.91 |
Full Cash Flow StatementMargins
Gross margin is 99.84%, with operating and profit margins of -203.06% and -204.93%.
| Gross Margin | 99.84% |
| Operating Margin | -203.06% |
| Pretax Margin | -203.81% |
| Profit Margin | -204.93% |
| EBITDA Margin | -199.98% |
| EBIT Margin | -203.06% |
| FCF Margin | -212.5% |
